Success Metrics

Clinical Success Rate
78.1%

Based on 25 completed trials

Completion Rate
78%(25/32)
Active Trials
0(0%)
Results Posted
16%(4 trials)
Terminated
7(21%)

Phase Distribution

Ph not_applicable
1
3%
Ph phase_2
13
38%
Ph early_phase_1
1
3%
Ph phase_1
15
44%
Ph phase_3
4
12%

Phase Distribution

16

Early Stage

13

Mid Stage

4

Late Stage

Phase Distribution34 total trials
Early Phase 1First-in-human
1(2.9%)
Phase 1Safety & dosage
15(44.1%)
Phase 2Efficacy & side effects
13(38.2%)
Phase 3Large-scale testing
4(11.8%)
N/ANon-phased studies
1(2.9%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

78.1%

25 of 32 finished

Non-Completion Rate

21.9%

7 ended early

Currently Active

0

trials recruiting

Total Trials

34

all time

Status Distribution
Completed(25)
Terminated(7)
Other(2)

Detailed Status

Completed25
Terminated7
unknown2

Development Timeline

Analytics

Development Status

Total Trials
34
Active
0
Success Rate
78.1%
Most Advanced
Phase 3

Trials by Phase

Early Phase 11 (2.9%)
Phase 115 (44.1%)
Phase 213 (38.2%)
Phase 34 (11.8%)
N/A1 (2.9%)

Trials by Status

unknown26%
completed2574%
terminated721%

Recent Activity

0 active trials
Showing 5 of 34
completedphase_3

Daunorubicin Hydrochloride, Cytarabine and Oblimersen Sodium in Treating Patients With Previously Untreated Acute Myeloid Leukemia

NCT00085124
terminatedearly_phase_1

Oblimersen Sodium & Combination Chemotherapy in Treating Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma

NCT00736450
terminatedphase_1

A Phase I/II Study of Oblimersen Plus Cisplatin and Fluorouracil in Gastric & Esophageal Junction Cancer

NCT00064259
completedphase_2

Oblimersen, Thalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma

NCT00049374
terminatedphase_1

Oblimersen Plus Doxorubicin and Docetaxel in Treating Patients With Metastatic or Locally Advanced Breast Cancer

NCT00063934
View all 34 trials

Clinical Trials (34)

Showing 20 of 34 trialsScroll for more
NCT00085124Phase 3

Daunorubicin Hydrochloride, Cytarabine and Oblimersen Sodium in Treating Patients With Previously Untreated Acute Myeloid Leukemia

Completed
NCT00736450Early Phase 1

Oblimersen Sodium & Combination Chemotherapy in Treating Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma

Terminated
NCT00064259Phase 1

A Phase I/II Study of Oblimersen Plus Cisplatin and Fluorouracil in Gastric & Esophageal Junction Cancer

Terminated
NCT00049374Phase 2

Oblimersen, Thalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma

Completed
NCT00063934Phase 1

Oblimersen Plus Doxorubicin and Docetaxel in Treating Patients With Metastatic or Locally Advanced Breast Cancer

Terminated
NCT00047229Phase 2

Oblimersen and Doxorubicin in Treating Patients With Advanced Hepatocellular Carcinoma (Liver Cancer)

Completed
NCT00039117Phase 1

Oblimersen, Cytarabine, and Daunorubicin in Treating Older Patients With Acute Myeloid Leukemia

Completed
NCT00054639Phase 2

Oblimersen Sodium and Rituximab in Treating Patients With Recurrent B-cell Non-Hodgkin Lymphoma

Completed
NCT00017589Phase 2

Oblimersen and Gemtuzumab Ozogamicin in Treating Older Patients With Relapsed Acute Myeloid Leukemia

Completed
NCT00030641Phase 2

Docetaxel With or Without Oblimersen in Treating Patients With Non-Small Cell Lung Cancer

Unknown
NCT00016263Phase 3

Dacarbazine With or Without Oblimersen (G3139) in Treating Patients With Advanced Malignant Melanoma

Completed
NCT00017602Phase 3

Dexamethasone With or Without Oblimersen in Treating Patients With Relapsed or Refractory Multiple Myeloma

Completed
NCT00070343Not Applicable

Oblimersen and Dacarbazine in Treating Patients With Advanced Malignant Melanoma That Has Responded to Treatment on Clinical Trial GENTA-GM301

Unknown
NCT00024440Phase 3

Fludarabine and Cyclophosphamide With or Without Oblimersen in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia

Completed
NCT00059813Phase 2

Oblimersen and Interferon Alfa in Treating Patients With Metastatic Renal Cell Cancer

Completed
NCT00003103Phase 1

Chemotherapy in Treating Patients With Solid Tumors

Completed
NCT00091078Phase 2

Oblimersen and Imatinib Mesylate in Treating Patients With Advanced Gastrointestinal Stromal Tumors That Cannot Be Removed By Surgery

Terminated
NCT00049192Phase 2

Oblimersen and Imatinib Mesylate in Treating Patients With Chronic Myelogenous Leukemia

Completed
NCT00079131Phase 2

Oblimersen in Treating Patients With Merkel Cell Carcinoma

Completed
NCT00062244Phase 1

Oblimersen in Treating Patients With Relapsed or Refractory Waldenstrom's Macroglobulinemia

Completed

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
34